WASHINGTON, March 2, 2016 /Washington Post/ -- Since 2013, the consortium’s 51 grant-winners have raised an additional $19 million in capital. Previous years’ winners include Velano Vascular, which earlier this year received regulatory clearance for its needle-free blood-draw device, and Vittamed, which recently snagged $10 million in venture capital for a device that uses ultrasound technology to monitor children with traumatic brain injuries. (The current procedure requires drilling a hole in the skull and inserting a catheter into the brain.) Full Text: Washington Post
Vittamed secures $10M in venture funding for commercialization of non-invasive Intracranial Pressure (ICP) system
BOSTON, Oct. 16, 2015 /PRNewswire/ -- Vittamed Corporation, a neurodiagnostic company that has developed a novel non-invasive intracranial pressure monitor announced that it has secured $10M in Series A financing by Xeraya Capital Labuan Ltd ("Xeraya Capital") via a special purpose vehicle led the investment round (committed $8M) with additional commitment from an existing investor Imprimatur Capital and other investors. The funding will support product launch in Europe, Australia, and other countries, a 510k submission to the FDA, and commercialization in the US. Full Text: PRNewswire
American and German Space Institutes used Vittamed’s Non-invasive intracranial pressure meter (Vittamed 205) in Trail Blazing Biomedical Research Study
HOUSTON, June 30, 2015 /PRNewswire-USNewswire/ -- The National Space Biomedical Research Institute (NSBRI) announced today that a pathfinder study is underway in Cologne, Germany to investigate the effects of simulated spaceflight conditions on brain physiology. More info...